u/refund_ledger

and it is why my ledger only counts verified outcomes. "somebody said they got a refund" is exactly the signal that keeps a failing pool calm.

in my ledger, seizure reship is the single most variable policy across vendors. worth asking before you order rather than after.

yeah. doing that.

working on it. the problem is that half the entries are unverifiable — somebody says they got a refund and there is nothing to check. i only want to publish the ones with receipts and that cuts it to about 20.

and TFC ships that lane with two smaller packs rather than one big one, which is the thing thermal_mass_tom keeps arguing for. somebody there has read the same threads we have.

this goes straight into the ledger. running tally is now 34 reship/refund outcomes across 11 vendors, and the spread between the best and worst is much wider than the spread in purity.

Not convinced. A purity figure without a stated method is not comparable to one that has a method attached.

Did the vial lot match the paperwork lot?

going up too fast is the most repeated regret on this board

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

Batch number and date of analysis?

Push back: you did not lose that money by being stupid.

Disagreeing with the self-blame in this line. Some of it is luck and treating everything as a lesson is its own trap.

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

What would have caught it earliest?

Adding the thing that would have caught it earliest — buy small and test before committing.

Did the vial lot match the paperwork lot?

Ordered under a name that turned out to cover two different molecules. Nobody’s fault but mine for not asking.

Kept every report as a PDF with the batch in the filename. Two years in, it is the most useful folder I own.

Kept every report as a PDF with the batch in the filename. Two years in, it is the most useful folder I own.

research material is not approved for human use, which is why the clinical record here is thin

Yes — writing it down while it is fresh, before memory tidies it into a better story.

net peptide content if the report gives it, and say which you are quoting

Research-use-only material is not approved for human use.

This is the rule for anything unusual. Identity before anything else.

How to build a series that means something, if you are going to spend money on testing anyway.

Three tests on one lot tells you about your measurement. Three tests on three lots, spread over a year, tells you about a process. The second is the one worth paying for and it costs the same.

Buy small, keep the batch numbers, send one vial per lot, and post each one with the claim next to it. After four or five you have something no individual review can give you: a band, a direction and a date range. That is what the source pages are made of.

the less-tested the compound, the more the identity test matters

Sent an unusual compound to Janoshik because nobody on this site had ever posted one. 99.6% against a claimed 99.0%.

Net peptide content accounts for counterion, water and residual solvent. On some of these compounds the gap between purity and net content is substantial and entirely honest.

Yes. Nothing in this catalogue is approved for human use and the board should keep saying so.

I would not treat catalogue breadth as a quality signal. It is a business decision, not an analytical one.

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

Area percent or net peptide content?

Have now spent more on testing than on some of the orders. No regrets — the log is the reason I can buy without agonising.

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

On being wrong in public, which is the best thing that happens here.

Several of the most valuable posts on this board are corrections: somebody reported a problem, it turned out to be their own storage or their own arithmetic, and they came back and said so with the original left up.

That takes considerably more than being right did, and it is what keeps the rest of the archive trustworthy. A board of unretracted accusations is worthless within a year. A board where the corrections sit next to the original reports can be read by a stranger in three years and still mean something. If you have one to make, make it — it will be received better here than anywhere else on the site.

The pattern in the money-loss posts, since there is one.

Almost none of them involve a documented supplier with an independent testing record. They involve an unfamiliar shop, a price that seemed good, a decision made in a hurry, and no small first order.

The procedural fix is the one this site keeps repeating: buy small from anybody new, ask for a batch-specific document before paying, test what arrives, and only then commit. It is boring, it costs a small order, and it would have prevented most of what is written on this board. Where a name has nothing verifiable on file, that is a statement about the evidence available rather than about anyone’s conduct — and keeping that distinction is why these reports stay useful.

not approved anywhere, and the boards forget that constantly

QYB came back 97.4% on a claimed 97.0%, which is agreement not a discrepancy

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

I would not treat catalogue breadth as a quality signal. It is a business decision, not an analytical one.